Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -2.02 is 95% above its 5-year average of -38.33, near the high end of its 5-year range (-63.00–-2.02).
72.29% above its 12-month average of -7.29.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.48.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 26 comparable quarters.
EARNINGS PER SHARE (EPS)
-2.02
EARNINGS PER SHARE (EPS) AVG TTM
-7.29
EARNINGS PER SHARE (EPS) AVG 3Y
-26.82
EARNINGS PER SHARE (EPS) AVG 5Y
-38.33
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+72.29%
CURRENT VS 3Y AVG
+92.47%
CURRENT VS 5Y AVG
+94.73%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Kalaris Therapeutics Inc
Market Cap
$63.41M
Earnings Per Share (EPS)
-2.02
TTM Avg
-7.29
3Y Avg
-26.82
5Y Avg
-38.33
Market Cap
$63.02M
Earnings Per Share (EPS)
-1.09
TTM Avg
-1.47
3Y Avg
-0.85
5Y Avg
-0.92
Market Cap
$64.05M
Earnings Per Share (EPS)
N/A
TTM Avg
-0.02
3Y Avg
-0.02
5Y Avg
-0.01
Market Cap
$64.56M
Earnings Per Share (EPS)
-55.66
TTM Avg
-39.81
3Y Avg
-97.72
5Y Avg
-154.19
Market Cap
$64.31M
Earnings Per Share (EPS)
-0.64
TTM Avg
-0.89
3Y Avg
-1.15
5Y Avg
-1.02
Market Cap
$64.94M
Earnings Per Share (EPS)
-0.19
TTM Avg
-0.10
3Y Avg
-0.67
5Y Avg
-1.24
Market Cap
$65.59M
Earnings Per Share (EPS)
-5.01
TTM Avg
-7.16
3Y Avg
-89.38
5Y Avg
-71.00
Market Cap
$60.43M
Earnings Per Share (EPS)
N/A
TTM Avg
-19.12
3Y Avg
-29.60
5Y Avg
-38.42
Market Cap
$58.77M
Earnings Per Share (EPS)
-13.20
TTM Avg
-15.24
3Y Avg
-17.58
5Y Avg
-15.68
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kalaris Therapeutics Inc (KLRS) | $63.41M | -2.02 | -7.29 | -26.82 | -38.33 |
| InterCure Ltd. (INCR)vs › | $63.02M | -1.09 | -1.47 | -0.85 | -0.92 |
| Alps Group Inc (ALPS)vs › | $64.05M | N/A | -0.02 | -0.02 | -0.01 |
| Gossamer Bio, Inc. (GOSS)vs › | $64.56M | -55.66 | -39.81 | -97.72 | -154.19 |
| PDS Biotechnology Corporation (PDSB)vs › | $64.31M | -0.64 | -0.89 | -1.15 | -1.02 |
| Heron Therapeutics, Inc. (HRTX)vs › | $64.94M | -0.19 | -0.10 | -0.67 | -1.24 |
| Cingulate Inc. (CING)vs › | $65.59M | -5.01 | -7.16 | -89.38 | -71.00 |
| Adicet Bio, Inc. (ACET)vs › | $60.43M | N/A | -19.12 | -29.60 | -38.42 |
| Fractyl Health, Inc. (GUTS)vs › | $58.77M | -13.20 | -15.24 | -17.58 | -15.68 |
| Fortress Biotech, Inc. (FBIO)vs › | $67.60M | 2.68 | -1.38 | -6.44 | -7.90 |
Trailing EPS (TTM)
$-2.02
Forward EPS (Est.)
$-2.01
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -2.85 |
| 2024-12-31 | -11.73 |
| 2023-12-31 | -42.09 |
| 2022-12-31 | -50.62 |
| 2021-12-31 | -63.00 |
| 2020-12-31 | -59.67 |
| 2019-12-31 | -8.42 |
| 2018-12-31 | -2.88 |
